Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 39

1.

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort and Risk-Based Screening.

Norton B, Southern WN, Steinman M, Smith BD, Deluca J, Rosner Z, Litwin AH.

Clin Gastroenterol Hepatol. 2016 Apr 19. pii: S1542-3565(16)30078-7. doi: 10.1016/j.cgh.2016.04.017. [Epub ahead of print]

PMID:
27108792
2.

A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study.

Southern WN, Norton B, Steinman M, DeLuca J, Drainoni ML, Smith BD, Litwin AH.

BMC Infect Dis. 2015 Dec 1;15:553. doi: 10.1186/s12879-015-1283-3.

3.

Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.

Litwin AH, Soloway IJ, Cockerham-Colas L, Reynoso S, Heo M, Tenore C, Roose RJ.

Int J Drug Policy. 2015 Oct;26(10):1014-9. doi: 10.1016/j.drugpo.2015.08.008. Epub 2015 Aug 20.

PMID:
26341685
4.

Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?

Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, Byrne J, Levin J, Bruggmann P, Dore GJ; International Network for Hepatitis in Substance Users.

J Hepatol. 2015 Oct;63(4):779-82. doi: 10.1016/j.jhep.2015.06.014. Epub 2015 Aug 4. No abstract available.

PMID:
26254264
5.

"Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment.

Batchelder AW, Peyser D, Nahvi S, Arnsten JH, Litwin AH.

Drug Alcohol Depend. 2015 Aug 1;153:66-71. doi: 10.1016/j.drugalcdep.2015.06.007. Epub 2015 Jun 9.

PMID:
26096534
6.
7.

Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL.

Int J Drug Policy. 2015 Oct;26(10):922-35. doi: 10.1016/j.drugpo.2015.05.002. Epub 2015 May 17. Review.

PMID:
26077144
8.

Sample size determinations for group-based randomized clinical trials with different levels of data hierarchy between experimental and control arms.

Heo M, Litwin AH, Blackstock O, Kim N, Arnsten JH.

Stat Methods Med Res. 2014 Aug 14. pii: 0962280214547381. [Epub ahead of print]

9.

Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics.

Nahvi S, Segal KS, Litwin AH, Arnsten JH.

Addict Sci Clin Pract. 2014 Jun 13;9:9. doi: 10.1186/1940-0640-9-9.

10.

Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program.

Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH.

J Health Care Poor Underserved. 2014 May;25(2):652-62. doi: 10.1353/hpu.2014.0096.

PMID:
24858874
11.

Physician nonadherence with a hepatitis C screening program.

Southern WN, Drainoni ML, Smith BD, Koppelman E, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Litwin AH.

Qual Manag Health Care. 2014 Jan-Mar;23(1):1-9. doi: 10.1097/QMH.0000000000000007.

PMID:
24368717
12.

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants.

J Viral Hepat. 2013 Nov;20(11):745-60. doi: 10.1111/jvh.12173. Review.

13.

Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Bruggmann P, Litwin AH.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S56-61. doi: 10.1093/cid/cit271. Review.

14.

"Damaging what wasn't damaged already": psychological tension and antiretroviral adherence among HIV-infected methadone-maintained drug users.

Batchelder AW, Brisbane M, Litwin AH, Nahvi S, Berg KM, Arnsten JH.

AIDS Care. 2013;25(11):1370-4. doi: 10.1080/09540121.2013.766303. Epub 2013 Feb 13.

15.

Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH.

J Subst Abuse Treat. 2012 Dec;43(4):424-32. doi: 10.1016/j.jsat.2012.08.007. Epub 2012 Oct 2.

16.

Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting.

Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN.

Am J Public Health. 2012 Nov;102(11):e115-21. doi: 10.2105/AJPH.2012.300659. Epub 2012 Sep 20.

17.

Social support networks and primary care use by HIV-infected drug users.

Ramaswamy M, Kelly PJ, Li X, Berg KM, Litwin AH, Arnsten JH.

J Assoc Nurses AIDS Care. 2013 Mar-Apr;24(2):135-44. doi: 10.1016/j.jana.2012.05.001. Epub 2012 Aug 4.

18.

Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk.

Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN.

Dig Liver Dis. 2012 Jun;44(6):497-503. doi: 10.1016/j.dld.2011.12.014. Epub 2012 Feb 18.

PMID:
22342471
19.

Impact of adherence counseling dose on antiretroviral adherence and HIV viral load among HIV-infected methadone maintained drug users.

Cooperman NA, Heo M, Berg KM, Li X, Litwin AH, Nahvi S, Arnsten JH.

AIDS Care. 2012;24(7):828-35. doi: 10.1080/09540121.2011.644231. Epub 2012 Jan 24.

20.

Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.

Litwin AH, Berg KM, Li X, Hidalgo J, Arnsten JH.

BMC Infect Dis. 2011 Nov 12;11:315. doi: 10.1186/1471-2334-11-315.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk